他汀类药物多效药理作用及其机制研究进展

赵心彬; 倪敏; 陶霞

doi:10.3969/j.issn.1006-0111.2013.01.005

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

x 关闭永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

他汀类药物多效药理作用及其机制研究进展

赵心彬, 倪敏, 陶霞

文章导航 > 药学实践与服务 > 2013 > 31(1): 19-21

赵心彬, 倪敏, 陶霞. 他汀类药物多效药理作用及其机制研究进展[J]. 药学实践与服务, 2013, 31(1): 19-21. doi: 10.3969/j.issn.1006-0111.2013.01.005

引用本文:

赵心彬, 倪敏, 陶霞. 他汀类药物多效药理作用及其机制研究进展[J]. 药学实践与服务, 2013, 31(1): 19-21. doi: 10.3969/j.issn.1006-0111.2013.01.005

ZHAO Xin-bin, NI Min, TAO Xia. Progress on the multiple pharmacological activity and mechanism of statins[J]. Journal of Pharmaceutical Practice and Service, 2013, 31(1): 19-21. doi: 10.3969/j.issn.1006-0111.2013.01.005

Citation:

ZHAO Xin-bin, NI Min, TAO Xia. Progress on the multiple pharmacological activity and mechanism of statins[J]. Journal of Pharmaceutical Practice and Service, 2013, 31(1): 19-21. doi: 10.3969/j.issn.1006-0111.2013.01.005

他汀类药物多效药理作用及其机制研究进展

doi: 10.3969/j.issn.1006-0111.2013.01.005

第二军医大学长征医院药学部, 上海 200003

Progress on the multiple pharmacological activity and mechanism of statins

Department of Pharmacy, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China

摘要: 他汀类是临床上治疗高胆固醇血症主要药物, 广泛应用于冠心病一级及二级预防。近年来研究表明,他汀类药物还具有降脂外的多重作用,包括改善血管内皮功能、抗炎症、抗氧化作用、稳定动脉粥样硬化和抗肿瘤作用等。本文围绕他汀类药物对血管疾病和肿瘤的作用及机制展开综述。
- 他汀类药物 /
- 血管疾病 /
- 肿瘤
Abstract: Statins were a mainstay in the treatment of hyperlipidemia and used in the primary and secondary prevention of coronary artery disease. Recent studies indicated that there were some cholesterol-independent or pleiotropic effects of statins, including improving endothelial function, decreasing oxidative stress, inhibiting inflammation, enhancing the stability of atherosclerotic plaques and used for anticancer therapy. The effects and mechanisms of statins on vascular disease and cancer were reviewed in this paper.
- statins /
- vascular disease /
- cancer

[1]	Liao JK, Laufs U. Pleiotropic effects of stains[J]. Annu Rev Pharmacol Toxicol, 2005,45:89.
[2]	Farwell WR,D'Avolio LW,Scranton RE,et al. Stains and prostate cancer diagnosis and grade in a veterans population[J].J Natl Cancer Inst, 2011, 103(11):885.
[3]	Vaughan CJ, Gotto AM. Update on statins: 2003[J].Circulation, 2004, 110:886.
[4]	Alonso R,Mata P. Sustained long-term improvement of arterial endothelial function in heterozygous familial hypercholesterolemia patients treated with simvastatin[J].Atherosclerosis,2001, 157:423.
[5]	Tsunekawa T,Hayashi T. Cerivastain,a hydroxymethylglutaryl coenzyme reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days[J].Circulation, 2001, 104:376.
[6]	Williams JK, Sukhova GK, Herring DM, et al. Pravastain has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys[J].J Am CollCardoil, 1998, 31:684.
[7]	Endres M, Laufs U. Effects of statins on endothelium and signaling mechanisms[J].Stroke, 2004, 35:2708.
[8]	Walter DH, Zeiher AM, Dimmeler S. Effects of statins on endothelim and their contribution to neovascularization by mobilization of endothelil progenitor cells[J].Coronary Artery Disease, 2004, 15:235.
[9]	陈巧玲,蔡宝祥.他汀类药物防治动脉粥样硬化作用研究进展[J].药学实践杂志,2006,24(6):321.
[10]	Assmus B, Urbich C, Aicher A, et al. HMG-CoA Reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes[J].Circulation Res, 2003, 92:1049.
[11]	Vasa M, Fichtlscherer S. Increase in circulating endotheliap progenitor cells by stain therapy in patients with stable coronary artery disease[J].Circulation, 2001, 103:2885.
[12]	Fukumoto Y, Libby P, Rabkin E, et al. Stains alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits[J].Circulation, 2001, 103:993.
[13]	Vincent L, Chen W, Hong L, et al. Inhibition of endothelial cell migration by cerivastation, an HMG-CoA reductase inhibitor:contribution to its anti-angiogenic effect[J].FEBS Lett, 2001, 495(3):159.
[14]	Yamakawa T,Tanaka S,Kamei J,et al. Pitavsatatin inhibits vascular Smooth muscle cell proliferation by inactivating extracellular signal-regulated kinase 1/2[J].J Atheroscler Thromb,2003,10(1):37.
[15]	Richard K. The Jupiter study, CRP screening, and aggressive statin therapy implications for the primary prevention of cardiovascular disease[J].Ther Adv Cardiovasc Dis, 2009,3(4):309.
[16]	李秋荣,王勤,曲环,等.瑞舒伐他汀对血脂正常的2型糖尿病患者血清高敏C 反应蛋白的作用[J].中华高血压杂志,2011,19(3):280.
[17]	Bonetti PO, Lerman LO, et al. Stain effects beyond lipid lowering-are they clinically relevant?[J].European Heart Journal, 2003, 24(3):225.
[18]	Giannotti G,Landmesser U. Endothelial dysfunction as an early sign of atherosclerosis[J].Herz, 2007, 32(7):568.
[19]	陈瑗,周玫.氧化应激-炎症在动脉粥样硬化发生发展中作用研究的新进展[J].中国动脉硬化杂志,2008, 16(10):757.
[20]	Hawk E, Viner JL. Statins and cancer—beyond the “one drug, one disease” model[J].N Engl J Med, 2005, 352(21):2184.
[21]	王磊,胡昌华.他汀类药物抗癌作用新机制[J].中国药学杂志,2010,45(23):1796.
[22]	Sassano A,Katsoulidis E,Antico G,et al. Suppressive effects of statins on actue promyelocytic leukemia cells[J].Cancer Res,2007, 67(9)4524.
[23]	Weis M,Heeschen C,Glassford AJ,et al. Statins have biphasic effects on angiogenesis[J].Circulation,2002, 105:739.
[24]	Fromigué O, Hamidouche Z, Marie PJ. Blockade of the RhoA-JNK-c-Jun-MMP2 cascade by atorvastatin reduces osteosarcoma cell invasion[J]. J Biol Chem,2008, 284(45):30549.
[25]	Cho SJ, Kim JS, Kim JM, et al. Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts,and attenuates colitisassociated colon cancer in mice[J]. Int J Cancer, 2008, 123:951.
[26]	李颖,张增叶,姜达.洛伐他汀对恶性黑色素瘤B16细胞株的作用及其机制的研究[J]. 实用肿瘤学杂志,2008,6:520.
[27]	江庭秀,顾伟英,邱国强,等.辛伐他汀联合阿糖胞苷对K562细胞增殖与凋亡的影响[J].白血病·淋巴瘤,2011,20(1):35.
[28]	张莉.他汀类药物调脂及非调脂作用的临床新进展[J].医学信息,2011,24(7):4248.
[29]	Khurana V,Beijjanki HR,Caldito G,et al. Statins reduce the risk of lung cancer in humans,a large case-control study of US veterans[J]. Chest,2007, 131(5):1282.
[30]	吴苏舒,刘玉明,陈静.他汀类药物调脂外临床应用概况[J].药学实践杂志,2007,25(1):4.

[1]	田硕, 厉建中. 转录因子ZNF24在肿瘤中的研究进展 . 药学实践与服务, 2023, 41(12): 710-713, 721. doi: 10.12206/j.issn.2097-2024.202204043
[2]	方宇昕, 李育, 刘宝姝, 董国强. 线性泛素连接酶复合体与去线性泛素化酶在肿瘤中的研究进展 . 药学实践与服务, 2023, 41(9): 534-539. doi: 10.12206/j.issn.2097-2024.202307045
[3]	高习清, 卢光照, 鲁莹, 邹豪. 活性氧自由基响应型脂质体在抗肿瘤研究中的应用进展 . 药学实践与服务, 2023, 41(1): 14-17. doi: 10.12206/j.issn.2097-2024.202105086
[4]	刘胜, 陈敏, 凃远珍. 基于前置审核系统优化的三唑类抗真菌药与他汀类药物相互作用精细化审核 . 药学实践与服务, 2022, 40(2): 175-179. doi: 10.12206/j.issn.1006-0111.202109126
[5]	丁佳宁, 马进原, 朱全刚. 长链非编码RNA人母系表达基因3在肿瘤发生中作用的研究进展 . 药学实践与服务, 2019, 37(5): 390-393,421. doi: 10.3969/j.issn.1006-0111.2019.05.002
[6]	姜文丽, 黄才国. 晚期非小细胞肺癌靶向治疗的研究进展 . 药学实践与服务, 2016, 34(4): 301-304,333. doi: 10.3969/j.issn.1006-0111.2016.04.004
[7]	陈自强, 张玮, 李玉平, 王晓宇. 纳米载药系统逆转肿瘤及骨肉瘤多药耐药的研究进展 . 药学实践与服务, 2016, 34(2): 103-105. doi: 10.3969/j.issn.1006-0111.2016.02.002
[8]	王欢, 佘岚, 王琳召, 马志强, 张欣荣, 杨峰. 氧化介孔碳球纳米粒作为紫杉醇载体的研究 . 药学实践与服务, 2015, 33(2): 114-118. doi: 10.3969/j.issn.1006-0111.2015.02.005
[9]	王欢, 马志强, 杨峰. 用于肿瘤治疗的小分子干扰RNA非病毒载体研究进展 . 药学实践与服务, 2015, 33(6): 498-501. doi: 10.3969/j.issn.1006-0111.2015.06.005
[10]	程君, 芮耀诚. 真核延长因子eEF1A功能研究进展 . 药学实践与服务, 2012, 30(2): 89-91,124. doi: 10.3969/j.issn.1006-0111.2012.02.003
[11]	周忻. 50例肿瘤科住院患者的中药用药情况分析 . 药学实践与服务, 2009, 27(1): 55-57.
[12]	章忱, 程康, 郭炜, 卫洪昌. 麝香保心丸对裸小鼠人结肠癌肝转移模型促血管新生因子及肿瘤生长的影响 . 药学实践与服务, 2007, (5): 295-296,302.
[13]	侯雪梅, 崔黎丽, 李国栋, 李卫华. 抗肿瘤药物靶向制剂研究进展 . 药学实践与服务, 2007, (5): 273-275,280.
[14]	吴苏舒, 刘玉明, 陈静. 他汀类药物调脂外临床应用概况 . 药学实践与服务, 2007, (1): 4-6.
[15]	庞晓军, 黄军章, 刘国勇, 李香乐. 肿瘤基因治疗研究进展 . 药学实践与服务, 2006, (1): 4-6.
[16]	丁力, 丁家崇, 郭葆玉. 抗肿瘤药物新靶点半胱天冬酶-10 . 药学实践与服务, 2006, (2): 76-79.
[17]	王彦, 刁亚英, 姜远英. ABC转运蛋白与肿瘤多药耐药 . 药学实践与服务, 2003, (1): 28-31.
[18]	王晶, 潘勇华, 王旭明, 刘建飞. 光敏剂及其临床应用进展 . 药学实践与服务, 2002, (2): 67-70.
[19]	范开华, 刘子文, 夏俊. 血卟啉二乙二醇对消化道肿瘤的光动力疗效观察 . 药学实践与服务, 2001, (2): 76-76.
[20]	范开华, 温定量, 周明惠, 夏俊. 2,7,12,18-四甲基-3,8-二(1-甲氧乙基)-13,17-二(3-乙胺基丙基)卟啉衍生物的合成及其光敏活性 . 药学实践与服务, 1999, (6): 344-346.